Trial Profile
FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN -BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIAS PATIENTS AT FIRST RELAPSE
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Acronyms FIL_BRB
- 14 Dec 2021 Final results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 01 Dec 2020 Status changed from active, no longer recruiting to completed.
- 06 Feb 2020 Planned End Date changed from 1 Jun 2020 to 1 Jul 2020.